Veterinary Hematology Outlook: Fresh Frozen Plasma & Red Cell Concentrates for Anemia & Coagulation
公開 2026/04/03 16:40
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Pet Whole Blood and Blood Components - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pet Whole Blood and Blood Components market, including market size, share, demand, industry development status, and forecasts for the next few years.
For veterinary hospitals, emergency clinics, and pet blood banks, the availability of safe, species-specific blood products is critical for treating hypovolemia, coagulation disorders, and hypoproteinemia caused by anemia, trauma, poisoning, or disease in companion animals. The global Pet Whole Blood and Blood Components market addresses this need through blood components and plasma proteins derived from healthy animal blood, produced via separation, purification, or recombinant DNA technology. Key types include fresh whole blood, frozen or refrigerated whole blood, plasma (fresh frozen plasma, stored frozen plasma), red blood cell concentrates, and plasma proteins (e.g., canine albumin injection). With the growing number of pet chronic diseases, surgical procedures, and emergency medical situations, a stable, safe, and standardized blood supply system is becoming increasingly urgent.
The global market for Pet Whole Blood and Blood Components was estimated to be worth US$ 825 million in 2025 and is projected to reach US$ 1572 million, growing at a CAGR of 9.8% from 2026 to 2032. In 2024, global production reached 913.51 kiloliters, with an average selling price of US$ 902 per liter. This robust growth reflects increasing pet healthcare expenditure and advanced veterinary medicine.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097305/pet-whole-blood-and-blood-components
Species-Specific Blood Products for Veterinary Transfusion Medicine
Pet blood products refer to blood components and plasma proteins derived from healthy animal blood, produced through separation, purification, or recombinant DNA technology, for use in treating pet diseases. Key types include fresh whole blood, frozen or refrigerated whole blood, plasma (fresh frozen plasma, stored frozen plasma), red blood cell concentrates, and plasma proteins (such as canine albumin injection). These products are used to treat hypovolemia, coagulation disorders, and hypoproteinemia caused by anemia, trauma, poisoning, or disease.
Species-specific compatibility is critical: canine blood for dogs, feline blood for cats. Blood typing (DEA 1.1 in dogs, AB system in cats) prevents transfusion reactions. Cross-matching before transfusion ensures safety. Components include packed red blood cells (PRBC) for anemia, fresh frozen plasma (FFP) for clotting factors, and cryoprecipitate for specific deficiencies.
Industry Segmentation: Species & End-Users
The Pet Whole Blood and Blood Components market is segmented by animal source and veterinary setting:
Canine: Largest segment, reflecting dog population and advanced canine medical care. A veterinary emergency hospital reported that canine PRBC transfusions are standard for trauma and immune-mediated hemolytic anemia.
Feline: Growing segment with increasing cat ownership and feline critical care. Feline blood typing and transfusion protocols are becoming standard in specialty practices.
Bovine: Source for plasma proteins (bovine albumin) used in veterinary medicine.
Sheep: Source for specific antibodies and research applications.
Others: Equine, rabbit, and other species.
Application Segments
Veterinary Hospital: Emergency and specialty hospitals performing transfusions for trauma, surgery, and critical care. A referral hospital reported annual blood product usage of 500+ units.
Clinic: Primary care clinics with in-house transfusion capabilities.
Other: Veterinary blood banks and research institutions.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Extended shelf-life additive solutions for RBC storage (42 days vs. 35 days). Pathogen reduction technologies for plasma products. Lyophilized (freeze-dried) plasma for field use and extended storage.
The trend toward veterinary blood banking and donor programs (volunteer pet donors) increases availability. Cross-matching and blood typing standardization improves transfusion safety. Recombinant plasma proteins (canine albumin) reduce infectious disease risk.
Regional Market Dynamics
North America leads the pet whole blood and blood components market, driven by high pet ownership, advanced veterinary care, and established veterinary blood banks. The United States dominates with significant transfusion medicine infrastructure.
Europe follows, with strong veterinary specialty medicine in the UK, Germany, and France. Asia-Pacific is the fastest-growing region, with increasing pet ownership, rising veterinary expenditure, and improving emergency care in China, Japan, South Korea, and Australia.
Competitive Landscape
Key players include Thermo Fisher Scientific, Moregate BioTech, Bovogen Biologicals (ANZCO Foods Healthcare), Pel-Freez, HemoStat Laboratories, CellSera Australia (Auckland BioSciences), Animal Technologies, Serana Europe, Lake Immunogenics, MoreCare Inc., and Nanjing BioChannel Biotechnology.
Market Segmentation
The Pet Whole Blood and Blood Components market is segmented as below:
By Company
Thermo Fisher Scientific
Moregate BioTech
Bovogen Biologicals (ANZCO Foods Healthcare)
Pel-Freez, LLC
HemoStat Laboratories
CellSera Australia (Auckland BioSciences)
Animal Technologies
Serana Europe
Lake Immunogenics
MoreCare. Inc.
Nanjing BioChannel Biotechnology Co., Ltd
Segment by Species
Canine
Feline
Bovine
Sheep
Others
Segment by Setting
Veterinary Hospital
Clinic
Other
Exclusive Industry Outlook
Looking ahead, the convergence of pet whole blood technology with veterinary blood banking, pathogen reduction, and recombinant proteins represents a significant growth opportunity. Development of universal donor blood products (DEA 1.1 negative for dogs). Point-of-care blood typing and cross-matching devices for emergency use. Additionally, the expansion of pet insurance and advanced veterinary care in emerging markets will drive demand for standardized blood products. The ability to offer pet whole blood and blood components that combine species specificity, safety, and availability—supported by donor screening and infectious disease testing—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
For veterinary hospitals, emergency clinics, and pet blood banks, the availability of safe, species-specific blood products is critical for treating hypovolemia, coagulation disorders, and hypoproteinemia caused by anemia, trauma, poisoning, or disease in companion animals. The global Pet Whole Blood and Blood Components market addresses this need through blood components and plasma proteins derived from healthy animal blood, produced via separation, purification, or recombinant DNA technology. Key types include fresh whole blood, frozen or refrigerated whole blood, plasma (fresh frozen plasma, stored frozen plasma), red blood cell concentrates, and plasma proteins (e.g., canine albumin injection). With the growing number of pet chronic diseases, surgical procedures, and emergency medical situations, a stable, safe, and standardized blood supply system is becoming increasingly urgent.
The global market for Pet Whole Blood and Blood Components was estimated to be worth US$ 825 million in 2025 and is projected to reach US$ 1572 million, growing at a CAGR of 9.8% from 2026 to 2032. In 2024, global production reached 913.51 kiloliters, with an average selling price of US$ 902 per liter. This robust growth reflects increasing pet healthcare expenditure and advanced veterinary medicine.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097305/pet-whole-blood-and-blood-components
Species-Specific Blood Products for Veterinary Transfusion Medicine
Pet blood products refer to blood components and plasma proteins derived from healthy animal blood, produced through separation, purification, or recombinant DNA technology, for use in treating pet diseases. Key types include fresh whole blood, frozen or refrigerated whole blood, plasma (fresh frozen plasma, stored frozen plasma), red blood cell concentrates, and plasma proteins (such as canine albumin injection). These products are used to treat hypovolemia, coagulation disorders, and hypoproteinemia caused by anemia, trauma, poisoning, or disease.
Species-specific compatibility is critical: canine blood for dogs, feline blood for cats. Blood typing (DEA 1.1 in dogs, AB system in cats) prevents transfusion reactions. Cross-matching before transfusion ensures safety. Components include packed red blood cells (PRBC) for anemia, fresh frozen plasma (FFP) for clotting factors, and cryoprecipitate for specific deficiencies.
Industry Segmentation: Species & End-Users
The Pet Whole Blood and Blood Components market is segmented by animal source and veterinary setting:
Canine: Largest segment, reflecting dog population and advanced canine medical care. A veterinary emergency hospital reported that canine PRBC transfusions are standard for trauma and immune-mediated hemolytic anemia.
Feline: Growing segment with increasing cat ownership and feline critical care. Feline blood typing and transfusion protocols are becoming standard in specialty practices.
Bovine: Source for plasma proteins (bovine albumin) used in veterinary medicine.
Sheep: Source for specific antibodies and research applications.
Others: Equine, rabbit, and other species.
Application Segments
Veterinary Hospital: Emergency and specialty hospitals performing transfusions for trauma, surgery, and critical care. A referral hospital reported annual blood product usage of 500+ units.
Clinic: Primary care clinics with in-house transfusion capabilities.
Other: Veterinary blood banks and research institutions.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Extended shelf-life additive solutions for RBC storage (42 days vs. 35 days). Pathogen reduction technologies for plasma products. Lyophilized (freeze-dried) plasma for field use and extended storage.
The trend toward veterinary blood banking and donor programs (volunteer pet donors) increases availability. Cross-matching and blood typing standardization improves transfusion safety. Recombinant plasma proteins (canine albumin) reduce infectious disease risk.
Regional Market Dynamics
North America leads the pet whole blood and blood components market, driven by high pet ownership, advanced veterinary care, and established veterinary blood banks. The United States dominates with significant transfusion medicine infrastructure.
Europe follows, with strong veterinary specialty medicine in the UK, Germany, and France. Asia-Pacific is the fastest-growing region, with increasing pet ownership, rising veterinary expenditure, and improving emergency care in China, Japan, South Korea, and Australia.
Competitive Landscape
Key players include Thermo Fisher Scientific, Moregate BioTech, Bovogen Biologicals (ANZCO Foods Healthcare), Pel-Freez, HemoStat Laboratories, CellSera Australia (Auckland BioSciences), Animal Technologies, Serana Europe, Lake Immunogenics, MoreCare Inc., and Nanjing BioChannel Biotechnology.
Market Segmentation
The Pet Whole Blood and Blood Components market is segmented as below:
By Company
Thermo Fisher Scientific
Moregate BioTech
Bovogen Biologicals (ANZCO Foods Healthcare)
Pel-Freez, LLC
HemoStat Laboratories
CellSera Australia (Auckland BioSciences)
Animal Technologies
Serana Europe
Lake Immunogenics
MoreCare. Inc.
Nanjing BioChannel Biotechnology Co., Ltd
Segment by Species
Canine
Feline
Bovine
Sheep
Others
Segment by Setting
Veterinary Hospital
Clinic
Other
Exclusive Industry Outlook
Looking ahead, the convergence of pet whole blood technology with veterinary blood banking, pathogen reduction, and recombinant proteins represents a significant growth opportunity. Development of universal donor blood products (DEA 1.1 negative for dogs). Point-of-care blood typing and cross-matching devices for emergency use. Additionally, the expansion of pet insurance and advanced veterinary care in emerging markets will drive demand for standardized blood products. The ability to offer pet whole blood and blood components that combine species specificity, safety, and availability—supported by donor screening and infectious disease testing—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ